RVNC 2Q20 results—6/30/20 cash=$494M—(a $17M decline from 3/31/20): https://investors.revance.com/news-releases/news-release-details/revance-reports-second-quarter-2020-financial-results-provides The US launch of Teoxane’s dermal fillers is on-track for 3Q20 (i.e. soon). Guidance for 2020 operating cash burn remains $220-230M.